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Background: The omega-3 long chain polyunsaturated fatty acid, docosahexaenoic 78 
acid (DHA), has proven effective at reducing fat storage in animal studies.  However, 79 
a systematic review of human trials found a lack of quality data to support or refute 80 
this hypothesis. 81 
Objective: To determine whether maternal DHA supplementation during the last half 82 
of pregnancy results in a lower body mass index (BMI) and percentage body fat mass 83 
(%BF) of children.  84 
Design: A follow-up of children at 3 and 5 years of age born to mothers enrolled in 85 
the DOMInO (DHA to Optimize Mother Infant Outcome) double-blind randomized 86 
controlled trial, in which women with a singleton pregnancy were provided with 87 
DHA-rich fish oil capsules (providing 800 mg DHA/d) or vegetable oil capsules 88 
(control group) in the second half of pregnancy. Primary outcomes were BMI z-score 89 
and %BF at 3 and 5 years of age. Potential interactions between prenatal DHA and 90 
PPARγ genotype, as a measure of genetic predisposition to obesity, were investigated.  91 
Results: 1614 children were eligible for the follow-up and 1531 (95%) consented and 92 
are included in the analysis. BMI z-scores and %BF of children in the DHA group did 93 
not differ from children in the control group at either 3 years (BMI z-score, adjusted 94 
mean difference 0.03, 95% CI -0.07 to 0.13, p=0.61; %BF, adjusted mean difference -95 
0.26, 95% CI -0.99 to 0.46, p=0.47) or 5 years (BMI z-score, adjusted mean 96 
difference 0.02, 95% CI -0.08 to 0.12, p=0.66; %BF, adjusted mean difference 0.11, 97 
95% confidence interval -0.60 to 0.82, p=0.75). No treatment effects were modified 98 
by the PPARγ genotype of the child. 99 
5 
 
Conclusions:  Maternal intake of DHA-rich fish oil during pregnancy does not affect 100 
the growth or body composition of children at 3 or 5 years, independent of genetic 101 




The prevalence of overweight and obesity has reached epidemic proportions in many 104 
Western countries, and there is an urgent need for effective intervention strategies. 105 
Compelling epidemiological and experimental animal data has indicated that 106 
overweight and obesity have early life origins, and that exposure to an inappropriate 107 
balance of nutrients during fetal life and/or in early infancy can permanently alter the 108 
properties of fat cells and predispose an individual to fatness (1,2). This has led to 109 
suggestions that nutritional interventions during the perinatal period are likely to be 110 
more effective than those later in life in producing lifelong reductions in body fat 111 
mass and improvements to metabolic health (3). 112 
 113 
In this context, there has been growing interest in an increased supply of omega-3 (n-114 
3) long chain polyunsaturated fatty acids (LCPUFA) during the perinatal period as a 115 
potential means to limit fat deposition and improve metabolic health outcomes in 116 
children (4,5). This is based on results from studies conducted in vitro and in adult 117 
humans and rodents which have demonstrated that the n-3 LCPUFA, in particular 118 
docosahexaenoic acid (DHA), inhibit the hyperplastic and hypertrophic expansion of 119 
fat depots and improve insulin sensitivity (6-11).  120 
 121 
Despite these apparent benefits of n-3 LCPUFA,  clinical studies designed to evaluate 122 
the effect of maternal DHA supplementation on body fat mass in children have 123 
produced mixed results (12). However, these studies have had a number of 124 
methodological limitations, including high rates of attrition, lack of statistical power 125 
and absence of appropriately sensitive measures of body composition (12). In 126 
addition, the potential impact of a genetic predisposition to obesity/type 2 diabetes on 127 
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the relationship between metabolic outcomes and maternal DHA supplementation has 128 
not yet been investigated.  129 
 130 
We here report on the follow-up of children of Adelaide mothers who participated in 131 
the DOMInO (DHA to Optimize Mother Infant Outcome) trial (13) at 3 and 5 years of 132 
age. The primary objective of this study was to determine the effect of increased 133 
prenatal DHA on body mass index (BMI) z-score and percentage body fat (%BF) in 134 
children. A secondary objective was to determine whether the effects of maternal 135 
DHA supplementation on these outcomes were dependent on the child’s genotype for 136 
the Pro/Ala single nucleotide polymorphism (SNP) in the PPARγ gene, which has 137 
been strongly associated with genetic predisposition to obesity and type 2 138 
diabetes(14).  139 
 140 
Subjects and Methods 141 
Study design  142 
This study involved a follow-up of children born to mothers enrolled in a registered, 143 
multi-center, double-blind, RCT called the DOMInO trial (ACTRN12605000569606, 144 
3 and 5 year follow-up: ACTRN12611001127998). The DOMInO trial methods have 145 
been published previously (13). Briefly, women with singleton pregnancies <21 146 
weeks’ gestation were randomized to the treatment or control group using a computer 147 
driven service, stratified by center and parity. Women allocated to the treatment group 148 
received three 500 mg capsules per day of DHA-rich fish oil (~800 mg/d DHA and 149 
100 mg/d eicosapentaenoic acid; Incromega 500 TG, Croda Chemicals, East 150 
Yorkshire, England) and women in the control group received three 500 mg vegetable 151 
oil capsules (without DHA) per day. Women were asked to take the capsules from 152 
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study entry until birth. The eligible children (n=1614, 97%) for the 3 and 5 year 153 
follow-up were born to all 1660 women enrolled in Adelaide centers (Flinders 154 
Medical Centre or Women’s and Children’s Hospital) and had not withdrawn from 155 
the study or died. All procedures were conducted in accordance with the study 156 
protocol and approved by the local institutional boards of each center. Written 157 
informed consent was obtained from the guardian of each child. 158 
 159 
Outcome Assessments 160 
Anthropometric assessments, BMI z-score and %BF, were conducted at the hospital 161 
study centers between 25 March 2009 and 4 October 2013. Assessments were 162 
administered by trained research staff blinded to treatment group allocation.  163 
 164 
Anthropometric assessments  165 
Body weight was measured without shoes and in underwear to the nearest 100g using 166 
electronic scales. Height without shoes was measured using a stadiometer. Waist-, 167 
head- and hip-circumferences were measured using a non-stretch tape. All measures 168 
were recorded in duplicate, or triplicate if the first 2 measures differed by >0.1kg 169 
(weight) or >0.5cm (height/girths), and averaged for analysis. Weight and height 170 
measurements were used to calculate BMI (weight in kg/height in metres2). The 171 
measures for each child were compared with standardized reference charts for the 172 
child’s age and sex to calculate their z-scores (15,16). Corrected ages were used for 173 
children born preterm (<37 weeks' gestation). The number of children classified as 174 
underweight (BMI<10th percentile), overweight (BMI>85th percentile) and obese 175 




Total fat and fat-free mass were assessed using Bioelectrical Impedance Spectroscopy 178 
(BIS) (17). Fat-free mass was derived from the measure of total body water using an 179 
equation previously validated for use in paediatric populations (18,19). %BF was then 180 
determined by subtracting the fat-free mass from the body weight, dividing by body 181 
weight and multiplying by 100. 182 
 183 
Systolic, diastolic and mean arterial blood pressure at 5 years of age were assessed in 184 
duplicate using a DINAMAP Procare V100 monitor (GE Health Care) with an 185 
appropriate sized cuff.  186 
 187 
Blood sample collection and processing 188 
Children were instructed to fast for at least 4 hours prior to their 5 year clinic 189 
appointment and blood samples (~5ml) were collected into tubes treated with EDTA, 190 
kept on ice until transfer to the laboratory and processed (centrifugation at 1,500 x g 191 
for 30 minutes at 4°C) within 24 hours. The plasma and buffy coat fractions were 192 
separated into aliquots and frozen at –80°C, and the red blood cells washed in sterile 193 
saline, lipids extracted into chloroform and used to assess fatty acid composition of 194 
the phospholipids as previously described (20). 195 
 196 
Determination of insulin sensitivity 197 
Glucose and insulin concentrations in the 5 year plasma samples were determined 198 
using an enzymatic assay (Thermo Electron, Pittsburgh, PA)  and human 199 
ultrasensitive insulin ELISA kit (ALPCO Diagnostics, Salem, NH) respectively. The 200 
intra- and inter-assay coefficients of variation for both assays were <10%. The fasting 201 
glucose and insulin measures were used to calculate the HOMA-IR index for each 202 
child according to the equation [glucose (mmol/l) x insulin (mU/l)]/22.5.  203 
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PPARγ genotyping  204 
DNA was extracted from 200µl of the 5 year buffy coat samples using the Qiagen 205 
DNA extraction kit (Qiagen Pty Ltd, Doncaster, Australia). PPAR genotyping of 206 
each child was undertaken by the Australian Genome Facility (AGRF) using TaqMan 207 
technology (Applied Biosystems, Foster City, CA, USA).  208 
 209 
Other measures 210 
In the DOMInO trial, maternal weight, height and BMI, parity, education and 211 
smoking status were collected at enrolment.  Weight and height of the biological 212 
mother of the child were re-measured by clinic staff at the time of the 5year 213 
assessments. Questions on home environment, education and employment of the 214 
primary carer and whether the participant had requested to be unblinded were also re-215 
asked at the time of the 3 and 5 year assessments.  216 
 217 
At both the 3 and 5 year follow-up, detailed information on care outside the home and 218 
general health of the child was collected at the clinic appointment. Information on 219 
feeding practices in the first 6-12 months, family food environment and the child’s 220 
habitual dietary intake, physical activity and screen time was collected using a 221 
structured questionnaire completed by the primary carer.  222 
 223 
Sample size and statistical analysis 224 
Follow-up of the 1660 children born to women enrolled in Adelaide-based centers 225 
would provide over 90% power to detect a 3% relative reduction in the mean BMI 226 
(16kg/m2 to 15.52kg/m2, standard deviation 1.6kg/m2), and a 2% absolute reduction in 227 
the mean %BF (25% to 23% at 3 years and 21% to 19% at 5 years, standard deviation 228 
5%), in boys and girls separately, allowing for 10% loss to follow-up (alpha=0.05). 229 
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All analyses were performed on an intention-to-treat basis, according to the treatment 230 
group allocated at randomization. Multiple imputation was performed separately by 231 
treatment group using chained equations to create 100 complete datasets for analysis, 232 
assuming that data were missing at random. The effect estimates from the imputed 233 
datasets were combined using Rubin’s rules (21). The primary analysis was based on 234 
imputed data and included all participants who consented to the follow-up study. 235 
Sensitivity analyses were performed on the available data and on imputed data for all 236 
1660 children born to women enrolled in Adelaide-based centers. All analyses 237 
produced similar results and only the results of the primary analysis are presented. 238 
 239 
Continuous outcomes were analyzed using linear regression models, with treatment 240 
effects expressed as differences in means. For continuous outcomes that were log 241 
transformed prior to analysis, treatment effects are expressed as ratios of geometric 242 
means on the original scale. Binary outcomes were analyzed using log binomial 243 
regression models, with treatment effects expressed as relative risks (RRs). For 244 
outcomes measured at both 3 and 5 years, the repeated measurements were taken into 245 
account using generalized estimating equations, with treatment effects estimated at 246 
each time point separately. A priori secondary analyses were performed to test for 247 
effect measure modification by sex and PPARγ genotype.  248 
 249 
Both unadjusted and adjusted analyses were performed, with adjustment for the 250 
stratification variables, center and parity, as well as pre-specified variables 251 
depending on the outcome that included the child’s sex and PPARγ genotype and the 252 
mother’s secondary education, further education, smoking status and BMI at 253 
enrolment. Statistical significance was assessed at the 2-sided P<0.05 level. No 254 
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adjustment was made for multiple comparisons and results of secondary analyses 255 
should be interpreted with caution unless highly significant.  256 
 257 
Post-randomization child demographics and clinical characteristics were compared 258 
between treatment groups based on the available data using chi-square tests for 259 
categorical variables, Mann-Whitney U tests for continuous variables and log Poisson 260 
regression for count variables. All analyses followed a pre-specified statistical 261 
analysis plan and were performed using SAS version 9.3 (Cary, NC, USA). 262 
 263 
Results 264 
Participant flow and baseline characteristics 265 
Participant flow is shown in Figure 1. A total of 1531 families consented to the 3 and 266 
5 year follow-up (92.2% of the 1660 originally enrolled in Adelaide centers and 267 
94.9% of the 1614 invited to participate). BMI z-scores and %BF were determined for 268 
1468/1531 (95.9%) and 1269/1531 (82.9%) children respectively at 3 years and 269 
1352/1531 (88.3%) and 1120/1531 (73.2%) children respectively at 5 years. The 270 
amount of missing data requiring imputation was similar between the treatment 271 
groups.  272 
 273 
The sociodemographic characteristics of the families in the subset consenting to 274 
follow-up were comparable between the treatment groups at baseline (Table 1) and at 275 
3 and 5 years (Supplementary Table 1). The distribution of PPARγ genotypes in the 276 
children was similar between groups (Table 1).  277 
 278 
BMI z-score and %BF 279 
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The BMI z-scores of children in the DHA group did not differ from the control group 280 
at either 3 years (Table 2; adjusted mean difference 0.03, 95% CI -0.07 to 0.13, 281 
P=.61) or 5 years (Table 2; adjusted mean difference 0.02, 95% CI -0.08 to 0.12, 282 
P=.66). The %BF was also not different between children in the DHA and control 283 
groups at either 3 or 5 years (Table 2, 3 years, adjusted mean difference -0.26, 95% 284 
CI -0.99  to 0.46, P=.47; 5 years, adjusted mean difference 0.11, 95% CI -0.60  to 285 
0.82,  P=.75). There were no significant interactions between treatment group and 286 
either sex or PPARγ genotype in relation to BMI z-score or %BF at 3 or 5 years of 287 
age (data not shown).There was no difference in the proportion of children classified 288 
as overweight or obese between the treatment groups at either 3 or 5 years (Table 2).  289 
 290 
Other anthropometric outcomes 291 
Bodyweight and height z-scores were similar between groups, as was the average 292 
weight gain between 3 and 5 years of age (Table 2). Hip and waist circumferences 293 
and waist circumference z-scores were also not different between the treatment 294 
groups at either 3 or 5 years (Table 2). The waist:hip ratio was slightly higher in the 295 
DHA group compared to the control group at 3 years (adjusted mean difference, 0.00, 296 
95% CI 0.00 to 0.01, P=.04), but was not different between groups at 5 years (P=.43). 297 
Total and percentage fat-free mass, total body water and the impedance index was not 298 
different between groups at either 3 or 5 years (Table 2). Head circumference, head 299 
circumference z-score and the change in head circumference between 3 and 5 years 300 
were also similar between groups (Table 2). 301 
 302 
 303 
Insulin sensitivity at 5 years of age 304 
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In both adjusted and unadjusted analyses, insulin resistance at 5 years of age, as 305 
assessed by HOMA-IR, was higher in children in the DHA group compared to 306 
controls (Table 3;adjusted ratio of geometric means, 1.20, 95% CI 1.04 to 1.39, 307 
P=.01). Fasting insulin levels were also higher in the DHA group (adjusted ratio of 308 
geometric means, 1.17, 95% CI 1.03 to 1.33, P=.02). There was an interaction 309 
between treatment group and sex for fasting glucose concentrations (P=.03), such that 310 
boys in the DHA group had higher fasting glucose concentrations than boys in the 311 
control group (adjusted mean difference 0.21, 95% CI 0.01 to 0.42, P=.04), however 312 
there were no differences between groups in girls. Similar effects were observed 313 
for both fasting insulin concentrations and HOMA-IR. Boys in the DHA group had 314 
significantly higher mean HOMA-IR (adjusted ratio of geometric means 1.35, 95% CI 315 
1.11 to 1.65, P=.003) and fasting insulin levels (adjusted ratio of geometric means 316 
1.26, 95% CI 1.05 to 1.51, P=.01) compared with the control group, while no 317 
differences were seen for girls, however, the interactions between treatment and 318 
sex were not significant for HOMA-IR (P=.13) or fasting insulin (P=.28).  All 319 
results were independent of the PPARγ genotype of the child. 320 
 321 
Other post-randomization variables 322 
More families from the control group had requested to be un-blinded compared with 323 
the DHA group at both the 3 and 5 year time-points, but these represented <10% of 324 
the cohort. Maternal and paternal BMI at baseline and at the time of the 3 and 5 year 325 
follow-up was also similar between groups (Supplementary Table 1).  326 
 327 
There were no significant differences between groups in frequency of hospitalizations 328 
or diagnosis of any medical conditions between birth and 5 years (Supplementary 329 
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Table 2) or habitual dietary intake, family food environment or reported levels of 330 
physical activity or screen time at either 3 or 5 years (Supplementary Table 3). 331 
Systolic, diastolic and mean arterial blood pressure and fatty acid composition of red 332 
blood cell phospholipids at 5 years of age were also similar between groups 333 
(Supplementary Table 4). 334 
 335 
Discussion 336 
The results of this study do not support the hypothesis that increasing maternal DHA 337 
intake by 800mg/day during the second half of pregnancy can influence body weight, 338 
BMI z-score or body fat mass of the children either positively or negatively.   We 339 
have many reasons to have a high degree of confidence in our findings. The DOMInO 340 
trial is the largest RCT of DHA supplementation during pregnancy, and has high 341 
retention and long-term follow-up rates of the children. It is also the first study to 342 
include two measures of obesity/body fat mass, i.e. BIS and BMI z-score, at two ages 343 
and to investigate the potential impact of child genotype on their response to the 344 
prenatal DHA intervention.  345 
 346 
The percentage of DOMInO children classified as overweight or obese, >30% at 3 347 
years and >25% at 5 years, is similar to figures reported in previous studies of pre-348 
school children in South Australia by us (22) and others (23), indicating that this 349 
study population is representative of the general Australian pediatric population.  Our 350 
new data confirm that the percentage of overweight and obese children in Australia 351 
remains high at 5 years of age, despite the fact that this is considered to be a period of 352 
increased physical activity and lower BMI/fat mass which precedes the adiposity 353 




Our study suggests a possible negative effect of prenatal DHA supplementation on 356 
waist:hip ratio and insulin sensitivity. An increased waist circumference has 357 
previously been reported in children at 2.5 years whose mothers were supplemented 358 
with DHA during lactation (5). While ours is the first study to determine the effect of 359 
prenatal DHA supplementation on insulin sensitivity, our findings are unexpected 360 
given existing data from in vitro and experimental animal studies suggesting that 361 
DHA increases insulin sensitivity (25,26). While it is possible that the observed 362 
differences in insulin sensitivity and waist:hip ratio may indicate a true underlying 363 
adverse effect of DHA supplementation, these were secondary outcomes and as such  364 
require confirmation. It is also important to note that the differences between groups 365 
were small and that the measures in both groups fell within the normal range.   366 
 367 
The PPARγ Pro12Ala SNP is present in ~20% of Caucasian populations and has been 368 
consistently associated with a reduced risk of obesity and type 2 diabetes in 369 
epidemiological studies (14,27). While there were no significant interactions between 370 
PPARγ genotype and treatment in our study, we were likely underpowered to detect 371 
such interaction effects, and further studies will be needed to explore possible 372 
interactions.  373 
 374 
In light of the fact that ~70% of pregnant women in Adelaide are now consuming 375 
nutritional supplements which provide at least some DHA, it is encouraging that this 376 
long-term follow-up of the DOMInO trial showed no detrimental effects of maternal 377 
DHA supplementation on childhood growth or body composition. These data, 378 
together with the absence of significant effects on development in this same study 379 
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population at 4 years(28), support the safety of high-dose DHA supplements in 380 
pregnancy for the long term health of the child. 381 
 382 
Conclusion  383 
The results of this follow-up study provide no evidence to support the hypothesis that 384 
increasing maternal DHA intake during the second half of pregnancy influences body 385 
weight, BMI or body fat mass of the children, at least up to 5 years of age. We cannot 386 
extend our conclusion to suggest that maternal DHA intake does not influence later 387 
fat deposition in the child, however, it seems that any effects on growth are likely 388 
small, and are far outweighed by the influence of other factors, such as genetics and 389 
environment, experienced by the child after birth. This trial therefore provides the 390 
most robust data to date that maternal DHA supplementation during pregnancy is not 391 
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Maternal data collected at enrolment   
 Primiparous, n (%) 319 (41.4) 321 (42.2) 
 Mother completed secondary education, n(%)  485 (63.0) 495 (65.0) 
 Mother completed further education, n (%)a 515 (66.9) 533 (70.0) 
 
Non-smoker before and during early pregnancy, 
n(%) 
556 (72.2) 512 (67.3) 





Infant pre-randomization characteristics   
Infant female sex, n(%) 384 (49.9) 382 (50.2) 
PPARγ Pro12Ala genotype, n(%)b   
Pro/Pro 260 (77.6) 245 (77.3) 
 Pro/Ala 66 (19.7) 66 (20.8) 
Ala/Ala 9 (2.7) 6 (1.9) 
a Degree, diploma, certificate, trade  
b Numbers do not add up to total in each group due to missing data. Percentages 




TABLE 2 . Primary and Secondary Anthropometric Outcomes at 3 and 5 years of age  






 Effect (95% CI) 
P 
Value Effect (95% CI) 
P 
Value 
3-years        
BMI z-score 0.72 (0.97) 0.70 (1.06) 0.02 (-0.08,0.12) 0.73 0.03 (-0.07,0.13) 0.61 
Percent Body Fat c 24.54 (7.07) 24.87 (6.69) -0.32 (-1.08,0.43) 0.40 -0.26 (-0.99,0.46) 0.47 
Body Weight (kg) 15.40 (2.02) 15.34 (2.01) 0.07 (-0.14,0.27) 0.53 0.08 (-0.12,0.27) 0.43 
Body Weight z-score 0.51 (0.97) 0.48 (0.95) 0.04 (-0.06,0.13) 0.43 0.04 (-0.05,0.14) 0.38 
BMI (kg/m2) 16.52 (1.41) 16.51 (1.54) 0.01 (-0.14,0.16) 0.92 0.02 (-0.13,0.16) 0.81 
BMI >85th percentile a 256 (33.2%) 287 (37.7%) 0.88 (0.77,1.01) 0.07 0.89 (0.78,1.02) 0.10 
BMI >90th percentile a 195 (25.4%) 216 (28.4%) 0.89 (0.76,1.06) 0.19 0.91 (0.77,1.07) 0.26 
BMI <10th percentile a 11 (1.4%) 21 (2.8%) 0.51 (0.24,1.07) 0.07 0.51 (0.24,1.07) 0.07 
Total Fat Mass (kg) 3.79 (1.26) 3.84 (1.25) -0.05 (-0.18, 0.09) 0.48 -0.03 (-0.17, 0.10) 0.62 
Total Fat-Free Mass (kg) 11.61 (1.76) 11.50 (1.68) 0.11 (-0.07, 0.20) 0.24 0.11 (-0.06, 0.27) 0.20 
Percent Fat-Free Mass c 75.43 (7.03) 75.13 (6.64) 0.30 (-0.44, 1.05) 0.43 0.24 (-0.47, 0.95) 0.51 
Total Body Water (kg) 8.68 (1.25) 8.59 (1.19) 0.09 (-0.04,0.22) 0.20 0.09 (-0.04, 0.21) 0.17 
Impedance Index 13.00 (2.02) 12.88 (1.91) 0.12 (-0.08,0.33) 0.23 0.12 (-0.07,0.32) 0.22 
Height (cm) 96.43 (4.21) 96.27 (4.04) 0.16 (-0.26,0.57) 0.45 0.16 (-0.23,0.55) 0.41 
Height z-score c 0.03 (1.04) -0.01 (0.97) 0.05 (-0.05,0.15) 0.36 0.05 (-0.06,0.15) 0.38 
Head Circumference (cm) c 50.04 (1.57) 50.06 (1.55) -0.02 (-0.17, 0.14) 0.84 -0.02 (-0.16, 0.13) 0.81 
Head Circumference z-score 0.69 (1.02) 0.69 (1.00) 0.00 (-0.11,0.10) 0.96 0.00 (-0.11,0.10) 0.96 
Waist Circumference (cm) c 50.73 (3.53) 50.50 (3.48) 0.23 (-0.12,0.59) 0.20 0.25 (-0.10,0.60) 0.17  
Waist Circumference z-score 0.47 (0.88) 0.40 (0.91) 0.07 (-0.02,0.16) 0.11 0.08 (-0.01,0.17) 0.09 
Hip Circumference (cm) c 53.65 (3.54) 53.66 (3.67) -0.01 (-0.38,0.35) 0.95 0.03 (-0.33,0.39) 0.87  
Waist:Hip ratio c 0.95 (0.05) 0.94 (0.04) 0.00 (0.00,0.01) 0.04 0.00 (0.00,0.01) 0.04  
5-years       
BMI z-score 0.56 (0.97) 0.54 (1.03) 0.01 (-0.09,0.12) 0.78 0.02 (-0.08,0.12) 0.66 
Percent Body Fat c 23.46 (6.82) 23.42 (6.59) 0.05 (-0.72,0.81) 0.91 0.11 (-0.60,0.82) 0.75 
Body Weight (kg) 19.95 (3.00) 19.87 (3.07) 0.09 (-0.22,0.39) 0.58 0.06 (-0.23,0.36) 0.68 
Body Weight z-score 0.45 (0.98) 0.42 (0.97) 0.03 (-0.06,0.13) 0.49 0.04 (-0.06,0.14) 0.43 
Body weight increase 3-5 years 
(kg) 4.51 (1.60) 4.47 (1.71) 0.04 (-0.13,0.22) 0.65 0.02 (-0.15,0.18) 0.85 
BMI (kg/m2) 16.19 (1.61) 16.20 (1.73) -0.01 (-0.18,0.16) 0.90 0.00 (-0.17, 0.17) 0.99 
BMI >85th percentile a 221 (28.7%) 223 (29.4%) 0.98 (0.83,1.15) 0.78 0.99 (0.84,1.16) 0.90 
BMI >90th percentile a 165 (21/5%) 168 (22.1%) 0.97 (0.80,1.19) 0.78 0.99 (0.81,1.20) 0.91 
BMI <10th percentile a 13 (1.7%) 19 (2.5%) 0.66 (0.31,1.40) 0.28 0.66 (0.31,1.40) 0.28 
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Total Fat Mass (kg) 4.75 (1.78) 4.74 (1.85) 0.01 (-0.18, 0.20) 0.92 0.02 (-0.17, 0.20) 0.86 
Total Fat-Free Mass (kg) c 15.25 (2.36) 15.15 (2.22) 0.11 (-0.14, 0.35) 0.40 0.08 (-0.15, 0.32) 0.48 
Percent Fat-Free Mass c 76.52 (6.80) 76.61 (6.52) -0.09 (-0.84, 0.67) 0.82 -0.15 (-0.85, 0.55) 0.67 
Total Body Water (kg) 11.32 (1.67) 11.24 (1.58) 0.08 (-0.10,0.26) 0.39 0.06 (-0.11,0.24) 0.48 
Impedance Index 16.98 (2.67) 16.88 (2.50) 0.10 (-0.17,0.38) 0.45 0.08 (-0.19,0.34) 0.56 
Height (cm) 110.82 (5.06) 110.58 (4.93) 0.24 (-0.27,0.75) 0.35 0.16 (-0.32, 0.65) 0.51 
Height z-score  0.12 (1.03) 0.08 (0.98) 0.04 (-0.06,0.14) 0.46 0.04 (-0.07,0.14) 0.48 
Height increase between 3 and 5 
years (cm) 
14.36 (2.66) 14.28 (2.75) 0.07 (-0.22,0.37) 0.61 -0.02 (-0.26,0.22) 0.86 
Head Circumference (cm) c 51.35 (1.53) 51.33 (1.56) 0.02 (-0.14, 0.18) 0.80 0.01 (-0.14, 0.16) 0.86 
Head Circumference z-score 0.66 (0.98) 0.64 (0.98) 0.02 (-0.09,0.13) 0.71 0.02 (-0.09,0.13) 0.71 
Head Circumference increase 
between 3 and 5 years (cm) 1.30 (0.86) 1.25 (0.91) 0.04 (-0.06,0.14) 0.40 0.03 (-0.07,0.13) 0.53 
Waist Circumference (cm) c 53.69 (3.88) 53.57 (4.24) 0.11 (-0.31,0.54) 0.60 0.10 (-0.31,0.51) 0.62 
Waist Circumference z-score 0.24 (0.74) 0.20 (0.79) 0.04 (-0.04,0.12) 0.34 0.04 (-0.04,0.12) 0.29 
Hip Circumference (cm) c 59.34 (4.16) 59.31 (4.55) 0.03 (-0.41,0.47) 0.90 0.04 (-0.40,0.48) 0.87 
Waist:Hip ratio c 0.91 (0.04) 0.90 (0.04) 0.00 (0.00,0.01) 0.47 0.00 (0.00,0.01) 0.43 
BMI z-score 0.72 (0.97) 0.70 (1.06) 0.02 (-0.08,0.12) 0.73 0.03 (-0.07,0.13) 0.61 
Data are presented as mean (SD) with effect being difference in means unless otherwise indicated. Analyses are based on 100 imputed datasets. 
aData are presented as number (percentage) with effect being relative risk.  
bAdjusted for center, parity, maternal BMI at study entry, mother’s secondary education, mother’s further education, mother’s smoking status, PPARγ genotype. 
c Also adjusted for infant sex and actual age of child at assessment.  
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Effect (95% CI) P Value 
Adjustedb 
 
Effect (95% CI) 
P 
Value 
HOMA-IR a 0.80 (0.43-1.71) 0.68 (0.38-1.31) 1.20 (1.04, 1.39) 0.01 1.20 (1.04, 1.39) 0.01 
Fasting Glucose 4.07 (1.08) 4.02 (1.02) 0.05 (-0.11, 0.20) 0.56 0.05 (-0.11, 0.20) 0.56 
Fasting Insulin a 4.63 (2.68-9.20) 4.01 (2.38-7.25) 1.17 (1.03, 1.32) 0.02 1.17 (1.03, 1.33) 0.02 
Boys       
HOMA-IR a 0.86 (0.44-1.88) 0.62 (0.35-1.21) 1.35 (1.11, 1.65) 0.003 1.35 (1.11, 1.65) 0.003 
Fasting Glucose 4.26 (1.07) 4.03 (1.00) 0.22 (0.02, 0.43) 0.03 0.21 (0.01, 0.42) 0.04 
Fasting Insulin a 4.75 (2.70-9.63) 3.63 (2.22-6.81) 1.25 (1.04, 1.50) 0.02 1.26 (1.05, 1.51) 0.01 
Girls       
HOMA-IR a 0.75 (0.43-1.58) 0.74 (0.41-1.41) 1.07 (0.86, 1.33) 0.55 1.07 (0.86, 1.33) 0.52 
Fasting Glucose 3.87 (1.04) 4.01 (1.04) -0.14 (-0.36, 0.09) 0.24 -0.12 (-0.35, 0.11) 0.29 
Fasting Insulin a 4.55 (2.66-8.90) 4.40 (2.56-7.72) 1.09 (0.90, 1.31) 0.37 1.09 (0.90, 1.31) 0.37 
Data are presented as mean (SD) with effect being difference in means unless otherwise indicated. Analyses are based on 100 imputed datasets. 
a Data are presented as median (IQR) with effect being ratio of geometric means. 
b Adjusted for center, parity, maternal BMI at study entry, infant sex, mother’s secondary education, mother’s further education, mother’s smoking 
status, PPARγ genotype. 
 
 
 
 
 
 
 
